Translating CRISPR-Cas Therapeutics: Approaches and Challenges

Area of Science:

• Biotechnology and Genetic Medicine
• Molecular Biology and Genomics

Background:

• CRISPR-Cas technology represents a significant advancement in gene editing.
• Early clinical trials are exploring its potential for treating genetic and epigenetic diseases.
• Translating CRISPR-Cas from the lab to the clinic faces numerous hurdles.

Purpose of the Study:

• To review the process of translating CRISPR-Cas therapeutics from technological systems to clinical modalities.
• To identify and analyze challenges in the therapeutic cascade, including delivery, manufacturing, and safety.
• To explore potential solutions for overcoming obstacles in CRISPR-Cas clinical translation.

Main Methods:

• Review of current CRISPR-Cas research and clinical trial data.
• Analysis of the therapeutic cascade for CRISPR-Cas based medicines.
• Identification of challenges and proposed solutions in CRISPR-Cas development.

Main Results:

• CRISPR-Cas clinical trials are initiating, demonstrating early therapeutic promise.
• Successful translation requires addressing complex issues in cargo, delivery, manufacturing, and administration.
• Safety and therapeutic target profiling are critical for clinical success.

Conclusions:

• The rapid advancement of CRISPR-Cas technology is built upon foundational gene therapy research.
• Overcoming translational challenges is crucial for realizing the full therapeutic potential of CRISPR-Cas.
• This review provides insights into the pathway of CRISPR-Cas from research to clinical application.